Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
Gynecologic Oncology
|
July 27, 2020
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)
Patrick Robelin, Michel Tod, Olivier Colomban, et al.
Gynecologic Oncology
|
November 18, 2018
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial
Clémence Romeo, Florence Joly, Isabelle Ray-Coquard, et al.
Plos One
|
October 11, 2018
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
Paul H Cottu, Jacques Bonneterre, Andrea Varga, et al.
The Lancet. Oncology
|
July 21, 2018
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
Amit M Oza, Ursula A Matulonis, Susanne Malander, et al.
Gynecologic Oncology
|
January 8, 2016
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study
Philipp Harter, Toby Johnson, Dominique Berton-Rigaud, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 18, 2019
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer
Domenica Lorusso, Felix Hilpert, Antonio González Martin, et al.
Bulletin Du Cancer
|
March 17, 2018
[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]
Marianne Lorcet, Alain Lortholary, Jean Emmanuel Kurtz, et al.
Molecular Cancer
|
August 13, 2024
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research
Aurélie Moniot, Christophe Schneider, Laure Chardin, et al.
BMC Medicine
|
December 11, 2025
Long-term quality of life in non-epithelial ovarian cancer survivors: TMRG-GINECO-Vivrovaire rare tumors case-control study
Coraline Dubot, Isabelle Ray-Coquard, Justine Lequesne, et al.
BMC Cancer
|
October 27, 2021
"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors"
François Gernier, Djihane Ahmed-Lecheheb, Patricia Pautier, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
Gynecologic Oncology
|
July 27, 2020
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)
Patrick Robelin, Michel Tod, Olivier Colomban, et al.
Gynecologic Oncology
|
November 18, 2018
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial
Clémence Romeo, Florence Joly, Isabelle Ray-Coquard, et al.
Plos One
|
October 11, 2018
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
Paul H Cottu, Jacques Bonneterre, Andrea Varga, et al.
The Lancet. Oncology
|
July 21, 2018
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
Amit M Oza, Ursula A Matulonis, Susanne Malander, et al.
Gynecologic Oncology
|
January 8, 2016
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study
Philipp Harter, Toby Johnson, Dominique Berton-Rigaud, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 18, 2019
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer
Domenica Lorusso, Felix Hilpert, Antonio González Martin, et al.
Bulletin Du Cancer
|
March 17, 2018
[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]
Marianne Lorcet, Alain Lortholary, Jean Emmanuel Kurtz, et al.
Molecular Cancer
|
August 13, 2024
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research
Aurélie Moniot, Christophe Schneider, Laure Chardin, et al.
BMC Medicine
|
December 11, 2025
Long-term quality of life in non-epithelial ovarian cancer survivors: TMRG-GINECO-Vivrovaire rare tumors case-control study
Coraline Dubot, Isabelle Ray-Coquard, Justine Lequesne, et al.
BMC Cancer
|
October 27, 2021
"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors"
François Gernier, Djihane Ahmed-Lecheheb, Patricia Pautier, et al.
Page
of 5